Post AMI Ventricular Septal Defect: Contemporary Results of Endovascular vs Surgical Repair

In the era of endovascular intervention, with shorter revascularization times, we see lower rates of mechanical complications due to acute myocardial infarction (AMI). Increased rates were recorded during the COVID-19 pandemic, but driven by delays in consultation. 

Comunicación interventricular post IAM: Resultados contemporáneos del tratamiento endovascular vs quirúrgico

Though occasional (with an estimated incidence of 0.2%), post AMI ventricular septal defect (VSD), or interventricular communication, involves high mortality.  Ischemic VSD will produce ischemia related disorders in addition to mechanically compromising the left-right shunt. Surgical repair with patch has been the preferred strategy for many years, though percutaneous closure is a valid strategy increasingly being used. 

This observational retrospective study of a registry in the UK gathered data from patients with post AMI VSD since 2010, aiming at comparing inhospital vs long term mortality. 

Data from 362 patients treated for post AMI VSD were in looked at, 231 were treated with surgery (93.4% patch) and 131 percutaneously (64% use of Amplatzer). Overall, patients treated with closure devices were older (72 vs 67 years; P<0.001) and had higher BMI (28 vs 26 kg/m2; P=0.01). On the other hand, surgical patients presented larger septum defects (18 vs 20mm, P<0.001) and were more often diagnosed with cardiogenic shock (51.9% vs 62.8%, P=0.044). 

Read also: Stent Thrombosis: Clinical Characteristics and Event Predictors in a Contemporary Cohort.

13% of patients treated percutaneously required an additional procedure (either surgical or percutaneous). Also, there was high crossover: 15% of endovascular patients required surgery and 7.4% of surgical patients required a closure device. 

In hospital mortality was 48.1%, with more events in the endovascular arm (55% vs 44.2%, P=0.048), whereas 5-year mortality saw no significant differences (61.1% vs 53.7%, P=0.17). Independent factors associated with mortality were cardiogenic shock (aHR 1.97, CI 95% 1.37-2.84; P<0.001) and initial percutaneous approach (aHR 1.44, CI 95% 1.01-2.05, P=0.042).

Conclusions

This study has shown that, despite the latest technological advance, mortality associated to ischemic VSD remains high, regardless the strategy. This study presents limitations because of high crossover. These patients should be treated either surgical or percutaneously, seeing as medical treatment alone rendered nearly 94% mortality rate.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry.

Reference: Giblett, Joel P et al. “Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry.” European heart journal, ehac511. 17 Sep. 2022, doi:10.1093/eurheartj/ehac511.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...